{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:26Z","timestamp":1786982726234,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40121-025-01252-w","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:35:22Z","timestamp":1763969722000},"page":"217-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03580668","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-4684","authenticated-orcid":false,"given":"Andrea","family":"Antinori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yokomaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Elinav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcsn\u00fc","family":"Pulluk\u00e7u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joss","family":"de Wet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Antela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sabranski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"den Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaw Yee","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marongiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jarrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"1252_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). The path that ends AIDS: UNAIDS global AIDS update; 2023. https:\/\/thepath.unaids.org\/wp-content\/themes\/unaids2023\/assets\/files\/2023_report.pdf. Accessed 27 Sep 2024."},{"key":"1252_CR2","unstructured":"World Health Organization (WHO). Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period\u00a02022\u20132030; 2022. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/6b18ac34-f56a-466e-9660-b5653cb52ef0\/content. Accessed 27 Sep 2024."},{"key":"1252_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/hiv.13427","volume":"24","author":"JV Lazarus","year":"2023","unstructured":"Lazarus JV, Van Hout MC, Fuster-Ruizdeapodaca MJ, Brown G, Guaraldi G. A call for health systems to monitor the health-related quality of life of people living with HIV. HIV Med. 2023;24:107\u201310.","journal-title":"HIV Med"},{"key":"1252_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0640-4","volume":"14","author":"JV Lazarus","year":"2016","unstructured":"Lazarus JV, Safreed-Harmon K, Barton SE, et al. Beyond viral suppression of HIV \u2013 the new quality of life frontier. BMC Med. 2016;14:94.","journal-title":"BMC Med"},{"key":"1252_CR5","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). Global AIDS strategy 2021\u20132026; 2020. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/global-AIDS-strategy-2021-2026_en.pdf. Accessed 18 Jun 2025."},{"key":"1252_CR6","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s40121-022-00678-w","volume":"11","author":"A Antela","year":"2022","unstructured":"Antela A, Bernardino JI, de Quiros JCL, et al. Patient-reported outcomes (PROs) in HIV infection: points to consider and challenges. Infect Dis Ther. 2022;11:2017\u201333.","journal-title":"Infect Dis Ther"},{"key":"1252_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","volume":"11","author":"D Wohl","year":"2018","unstructured":"Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48\u00a0weeks among participants in randomized, double-blind, phase\u00a0III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018;11:561\u201373.","journal-title":"Patient"},{"key":"1252_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40271-020-00413-y","volume":"13","author":"A Antinori","year":"2020","unstructured":"Antinori A, Cossu MV, Menzaghi B, et al. Patient-reported outcomes in an observational cohort of HIV-1-infected adults on darunavir\/cobicistat-based regimens: beyond viral suppression. Patient. 2020;13:375\u201387.","journal-title":"Patient"},{"key":"1252_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.13593","volume":"25","author":"S Esser","year":"2024","unstructured":"Esser S, Brunetta J, Inciarte A, et al. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts. HIV Med. 2024;25:440\u201353.","journal-title":"HIV Med"},{"key":"1252_CR10","unstructured":"US Food and Drug Administration (FDA). Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims; 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 27 Jan 2025."},{"key":"1252_CR11","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/S2352-3018(19)30345-5","volume":"7","author":"M Kall","year":"2020","unstructured":"Kall M, Marcellin F, Harding R, Lazarus JV, Carrieri P. Patient-reported outcomes to enhance person-centred HIV care. Lancet HIV. 2020;7:e59\u201368.","journal-title":"Lancet HIV"},{"key":"1252_CR12","unstructured":"European AIDS Clinical Society (EACS). EACS guidelines v12.1; 2024. https:\/\/eacs.sanfordguide.com\/. Accessed 15 Jan 2025."},{"key":"1252_CR13","unstructured":"Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2024. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed 14 Oct 2024."},{"key":"1252_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society\u2013USA panel. JAMA. 2023;329:63\u201384.","journal-title":"JAMA"},{"key":"1252_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2025.2456890","volume":"26","author":"B Trottier","year":"2025","unstructured":"Trottier B, Yang CJ, Watanabe D, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort. HIV Res Clin Pract. 2025;26:2456890.","journal-title":"HIV Res Clin Pract"},{"key":"1252_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1477-7525-1-25","volume":"1","author":"J Shahriar","year":"2003","unstructured":"Shahriar J, Delate T, Hays RD, Coons SJ. Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. Health Qual Life Outcomes. 2003;1:25.","journal-title":"Health Qual Life Outcomes"},{"key":"1252_CR17","unstructured":"Maruish ME. User's Manual for the SF-36v2 Health Survey. Lincoln, RI: Quality Metric Incorporated; 2011."},{"key":"1252_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","volume":"9","author":"A Woodcock","year":"2006","unstructured":"Woodcock A, Bradley C. Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version. Value Health. 2006;9:320\u201333.","journal-title":"Value Health"},{"issue":"Suppl. 3","key":"1252_CR19","first-page":"S638","volume":"22","author":"J Romaine","year":"2019","unstructured":"Romaine J, Murray M, Bradley C. PIH62 investigating the responsiveness to change of the HIV Treatment Satisfaction Questionnaire Change version (HIVTSQC) in overcoming ceiling effects in the HIV Treatment Satisfaction Questionnaire Status version (HIVTSQS). Value Health. 2019;22(Suppl. 3):S638\u20139.","journal-title":"Value Health"},{"key":"1252_CR20","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1080\/01621459.1988.10478722","volume":"83","author":"RJA Little","year":"1988","unstructured":"Little RJA. A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc. 1988;83:1198\u2013202.","journal-title":"J Am Stat Assoc"},{"key":"1252_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795\u2013807.","journal-title":"N Engl J Med"},{"key":"1252_CR22","first-page":"18","volume":"2","author":"A Liaw","year":"2022","unstructured":"Liaw A, Wiener M. Classification and regression by randomForest. R News. 2022;2:18\u201322.","journal-title":"R News"},{"key":"1252_CR23","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.csda.2011.09.024","volume":"56","author":"A Hapfelmeier","year":"2012","unstructured":"Hapfelmeier A, Hothorn T, Ulm K. Recursive partitioning on incomplete data using surrogate decisions and multiple imputation. Comput Stat Data Anal. 2012;56:1552\u201365.","journal-title":"Comput Stat Data Anal"},{"key":"1252_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-022-05911-w","volume":"15","author":"N Cesare","year":"2022","unstructured":"Cesare N, Were LPO. A multi-step approach to managing missing data in time and patient variant electronic health records. BMC Res Notes. 2022;15:64.","journal-title":"BMC Res Notes"},{"key":"1252_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jmii.2023.01.015","volume":"56","author":"LY Chen","year":"2023","unstructured":"Chen LY, Sun HY, Chuang YC, et al. Patient-reported outcomes among virally suppressed people living with HIV after switching to co-formulated bictegravir, emtricitabine and tenofovir alafenamide. J Microbiol Immunol Infect. 2023;56:575\u201385.","journal-title":"J Microbiol Immunol Infect"},{"key":"1252_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0313338","volume":"20","author":"Y Yokomaku","year":"2025","unstructured":"Yokomaku Y, Teruya K, Watanabe D, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in treatment-naive and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort. PLoS ONE. 2025;20:e0313338.","journal-title":"PLoS ONE"},{"key":"1252_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178953","volume":"12","author":"L Emuren","year":"2017","unstructured":"Emuren L, Welles S, Evans AA, et al. Health-related quality of life among military HIV patients on antiretroviral therapy. PLoS ONE. 2017;12:e0178953.","journal-title":"PLoS ONE"},{"key":"1252_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004154","volume":"20","author":"EW Butterly","year":"2023","unstructured":"Butterly EW, Hanlon P, Shah ASV, et al. Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: an individual participant data meta-analysis. PLoS Med. 2023;20:e1004154.","journal-title":"PLoS Med"},{"key":"1252_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/QAI.0b013e3181ce6afe","volume":"54","author":"FC Lampe","year":"2010","unstructured":"Lampe FC, Harding R, Smith CJ, Phillips AN, Johnson M, Sherr L. Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;54:500\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1252_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/QAI.0B013E31822D490A","volume":"58","author":"JS Gonzalez","year":"2011","unstructured":"Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV\/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1252_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1023\/A:1013050904635","volume":"10","author":"A Woodcock","year":"2001","unstructured":"Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res. 2001;10:517\u201331.","journal-title":"Qual Life Res"},{"key":"1252_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/09564624241308372","volume":"36","author":"A Antinori","year":"2025","unstructured":"Antinori A, Marchetti G, Esposito V, et al. Effectiveness, safety, and patient-reported outcomes of bictegravir\/emtricitabine\/tenofovir alafenamide in routine clinical care in Italy: 12-month results from the BICSTaR cohort. Int J STD AIDS. 2025;36:309\u201318.","journal-title":"Int J STD AIDS"},{"key":"1252_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/hiv.13728","volume":"26","author":"C Stephan","year":"2025","unstructured":"Stephan C, Spinner CD, Rieke A, et al. Effectiveness, safety, and patient-reported outcomes of emtricitabine\/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: final 24-month results from the prospective German TAFNES cohort study. HIV Med. 2025;26:239\u201351.","journal-title":"HIV Med"},{"key":"1252_CR34","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1097\/CORR.0000000000001341","volume":"478","author":"K Ogura","year":"2020","unstructured":"Ogura K, Yakoub MA, Christ AB, et al. What are the minimum clinically important differences in SF-36 scores in patients with orthopaedic oncologic conditions? Clin Orthop Relat Res. 2020;478:2148\u201358.","journal-title":"Clin Orthop Relat Res"},{"key":"1252_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/epirev\/mxx008","volume":"39","author":"TM Atkinson","year":"2017","unstructured":"Atkinson TM, Stover AM, Storfer DF, et al. Patient-reported physical function measures in cancer clinical trials. Epidemiol Rev. 2017;39:59\u201370.","journal-title":"Epidemiol Rev"},{"key":"1252_CR36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0895-4356(98)00108-5","volume":"51","author":"JE Ware Jr","year":"1998","unstructured":"Ware JE Jr, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1167\u201370.","journal-title":"J Clin Epidemiol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01252-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01252-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01252-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:27:47Z","timestamp":1767871667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01252-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01252-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrea Antinori reports consulting fees from AstraZeneca, Bavarian Nordic, Gilead Sciences, Inc., GSK, Merck, Moderna, Pfizer, and ViiV Healthcare; and travel grants from Gilead Sciences, Inc. Yoshiyuki Yokomaku reports honoraria from Chugai Pharmaceutical, Denka, Gilead Sciences, Inc., Janssen Pharmaceuticals, MSD, Roche Diagnostics, and ViiV Healthcare; membership of Second Committee on Drugs, Pharmaceutical Affairs and Food Sanitation Council (PAFSC) and membership of Review Committee on Adverse Drug Reactions, Pharmaceuticals and Medical Devices Agency (PMDA). Hila Elinav reports research grants and honoraria from Gilead Sciences, Inc. and GSK\/ViiV Healthcare; and participation in advisory boards for Gilead Sciences, Inc. and GSK\/ViiV Healthcare. H\u00fcsn\u00fc Pulluk\u00e7u reports honoraria, travel grants, and other interests from Gilead Sciences, Inc., GSK, Ilko, and Pharmactive. Joss de Wet reports consulting fees and travel grants from Gilead Sciences, Inc. and ViiV Healthcare; and honoraria from and participation in advisory boards for Gilead Sciences, Inc., Merck, and ViiV Healthcare. Antonio Antela reports honoraria from and participation in advisory boards for Gilead Sciences, Inc., Janssen Cilag, and ViiV Healthcare; and travel grants from Gilead Sciences, Inc. Po-Liang Lu reports honoraria and travel grants from Gilead Sciences, Inc. Michael Sabranski reports travel grant from Gilead Sciences, Inc. Fabrice Bonnet reports research grants, honoraria, and travel grants from Gilead Sciences, Inc., MSD, and ViiV Healthcare; and consulting fees from Gilead Sciences, Inc. and ViiV Healthcare. Jan den Hollander reports consulting fees from Gilead Sciences, Inc., MSD, and ViiV Healthcare. Arthur Jackson reports participation in an advisory board for Mundipharma; and serving as chair of the Cork Fast Track City HIV Committee. Chiaw Yee Choy reports research grant from the National Centre for Infectious Diseases, honoraria for speaking at the Multi-Specialty Medical Mega Conference 2024 from the conference organisers, and unpaid board membership for Action for AIDS. David Thorpe, Andrea Marongiu, and James Jarrett are employees of, and hold stock in, Gilead Sciences, Inc. Rebecca Harrison is an employee of IQVIA, contracted to work with Gilead Sciences, Inc. Marta Boffito reports research grants from Gilead Sciences, Inc., Moderna, MRC, MSD, Sanofi, Valneva, and ViiV Healthcare; consulting fees from Gilead Sciences, Inc., GSK, MSD, Roche, and ViiV Healthcare; and honoraria from AstraZeneca, Gilead Sciences, Inc., MSD, Pfizer, and ViiV Healthcare. Yeon-Sook Kim, Weiping Cai, and Fujie Zhang have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Each study in this analysis was conducted in accordance with the protocol and ethical principles derived from international guidelines, including the Declaration of Helsinki of 1964 and its later amendments, Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation guidelines for Good Clinical Practice, and all applicable laws, rules, and regulations. The protocols for each study were approved by an institutional review board or ethics committee. The master ethics committees\/central IRBs for the studies are as follows: BICSTaR Asia: National Health Group Domain, Specific Review Board Domain E; BICSTaR Canada: Veritas IRB Inc.; BICSTaR Europe: CPP \u2013 Ile-de-France \u2013 VII; Ethikkommission Der L\u00e4k Badenw\u00fcrttemberg; Mater Misericordiae University Hospital Research Ethics Committee; Ethics Medical Research Committee Beaumont Hospital; Galway University Hospitals Clinical Research Ethics Committee; Clinical Research Ethics Committee Cork Teaching Hospitals; Comitato Etico Territoriale Lombardia 1; Metc Cmo Nijmegen; Metc Medisch Ethische Toetsingscommissie Utrechtmetc; Toetsingscommissie Wetenschappelijk Onderzoek Rotterdam; Ceic H. Bellvitge, Marmara University Pendik; Cec \u2013 Hrar; Ec-West Midlands \u2013 The Black Country; BICSTaR Israel: IL-LEC-Hadassah Medical Center Helsinki Committee; IL-LEC-Tel Aviv Sourasky Medical Center Helsinki Committee; IL-LEC-Kaplan Medical Center Helsinki Committee; IL-LEC-Rambam Health Care Center Helsinki Committee; IL-LEC-Sheba Medical Center Helsinki Committee; BICSTaR Japan: Institutional Review Board for Clinical Research of National Hospital, Organization Osaka National Hospital; Institutional Review Board for Clinical Research of National Hospital, Organization Nagoya Medical Center; Institutional Review Board for Clinical Research of National Hospital, Organization Kyushu Medical Center; Institutional Review Board for the Independent Clinical Research of Hokkaido University Hospital; Institutional Review Board for Clinical Research of National Center for Global Health and Medicine; China study: Ethics Committee of Beijing Ditan Hospital Capital Medical University; Medical Ethics Committee of Guangzhou Eighth People's Hospital. Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}